NBIX FY2025 SEC EDGAR DEF 14A #71 of 168 in industry

Neurocrine Biosciences Inc CEO pay ratio

The CEO earned $13.4M in FY2025 against median worker pay of $273,341 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-15
Industry
Chemicals & Pharmaceuticals
Industry rank
#71/168

Data updated August 2026

Subscribe to Neurocrine Biosciences Inc CEO pay filing updates (RSS)

CEO-to-worker pay ratio
49:1
Below Average (Scale: 0–1000:1)
CEO pay
$13.4M
Median worker
$273,341

Answer first

Neurocrine Biosciences Inc's FY2025 CEO total of $13.4M ranks #360 of 1,423 complete filings; its 49:1 pay ratio ranks #982. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $273,341. Industry placement uses the FY2025 SIC-28 peer cohort (# 71 of 168, 58th percentile - above the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#360
$13.4M of 1,423 FY2025
Ratio rank
#982
49:1 of 1,423
Industry pct
58th
above the industry median pay ratio

How Neurocrine Biosciences Inc ranks nationally

Neurocrine Biosciences Inc CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$13,448,935 Top 25% higher than 75% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). Below this entry. $10,000,000–$12,500,000: 139 companies (10%). Below this entry. $12,500,000–$15,000,000: 91 companies (6%). This entry sits in this band. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Neurocrine Biosciences Inc vs. Chemicals & Pharmaceuticals peers

CEO total pay ($13.4M) against pay ratio (49:1) for Neurocrine Biosciences Inc (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both2820634.87652567.612484500.517316433.422148366.341.6:143.6:145.5:147.4:149.4:1CEO total payPay ratio (CEO : median worker)Neurocrine Biosciences Inc, CEO total pay: 13448935 · Pay ratio (CEO : median worker): 49:1Neurocrine Biosciences IncViking Therapeutics, Inc., CEO total pay: 21269833 · Pay ratio (CEO : median worker): 49:1Viking Therapeutics, Inc.Lsb Industries, Inc., CEO total pay: 5363883 · Pay ratio (CEO : median worker): 49:1Lsb Industries, Inc.Alnylam Pharmaceuticals, Inc., CEO total pay: 14984640 · Pay ratio (CEO : median worker): 48:1Alnylam Pharmaceuticals, Inc.Vaxcyte, Inc., CEO total pay: 14585904 · Pay ratio (CEO : median worker): 48:1Vaxcyte, Inc.Valhi Inc /de/, CEO total pay: 3699168 · Pay ratio (CEO : median worker): 48:1Valhi Inc /de/
Neurocrine Biosciences Inc vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Neurocrine Biosciences Inc's structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Neurocrine Biosciences Inc

Complete DEF 14A pay-ratio filings for this CIK across FY2021–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
49:1
FY2025
vs prior FY
+14:1
from FY2024 35:1
CEO $ YoY
+45%
$13.4M latest
Filings shown
5
FY2021–2025
Neurocrine Biosciences Inc CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2021 $14.1M - $151,162 51:1 -
2022 $11.9M -15% $155,698 45:1 -6:1
2023 $15.8M +32% $269,081 58:1 +13:1
2024 $9.3M -41% $265,089 35:1 -23:1
2025 $13.4M +45% $273,341 49:1 +14:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 914475, FY2021–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
49:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$13.4M
Companies in Industry
168
vs. Industry Median
Above
#71 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Neurocrine Biosciences Inc: MODEST · HEAVY pay ratio

Neurocrine Biosciences Inc's FY2025 CEO total $13.4M ranks #360 of 1,423 complete filings (higher third by dollars). the CEO earned 49× the median employee ($273,341) in FY2025.

Median employee $273,341 (ELITE-MED); MODEST · HEAVY stamps put about 49 median-wage years per CEO year.

CEO Total Pay

$13.4M

FY2025 Summary Compensation, above median

Pay Ratio

49:1

Below typical

Neurocrine Biosciences Inc in the higher-dollar third

Neurocrine Biosciences Inc's FY2025 CEO total $13.4M ranks #360 of 1,423 complete filings (higher third by dollars). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Neurocrine Biosciences Inc's $13.4M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #360 and ratio rank #982 split - treat 49:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$13.4M
Median Employee Pay
$273,341
Pay Ratio
49:1
Filing Date
2026-04-15

Company Info

Ticker
NBIX
CIK
914475
Industry
Chemicals & Pharmaceuticals
SIC Code
2836
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 914475, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Neurocrine Biosciences Inc's FY2025 CEO total $13.4M ranks #360 of 1,423 complete filings (higher third by dollars).

Read with Neurocrine Biosciences Inc

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · HEAVY · ELITE-MED.

Cricut, Inc. · HEAVY

ABS(ceo_total_comp) peer at $13.4M (Δ $7K lighter vs Neurocrine Biosciences Inc); MID · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Firstenergy Corp · HEAVY

ABS(ceo_total_comp) peer at $13.4M (Δ $9K lighter vs Neurocrine Biosciences Inc); MID · ELITE-MED vs this page's MODEST · HEAVY · ELITE-MED.
Reliance, Inc. · HEAVY

ABS(ceo_total_comp) peer at $13.4M (Δ $41K lighter vs Neurocrine Biosciences Inc); STEEP · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Green Brick Partners, Inc. · HEAVY

ABS(ceo_total_comp) peer at $13.4M (Δ $47K lighter vs Neurocrine Biosciences Inc); MID · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Viking Therapeutics, Inc. (SIC 28 pole)

Viking Therapeutics, Inc. stamps MODEST · PEAK nearest in-SIC by ABS(pay_ratio) to Neurocrine Biosciences Inc's MODEST filing.
National dual ranks · #360/#982

Neurocrine Biosciences Inc's FY2025 package sits #360 by CEO dollars and #982 by ratio under HEAVY · MODEST.
Ratio primer · MODEST

Neurocrine Biosciences Inc's MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Neurocrine Biosciences Inc (CIK 914475), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.